116 related articles for article (PubMed ID: 20734401)
61. Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.
Sorenson L; Fu Y; Hood T; Warren S; McEachron TA
Oncoimmunology; 2019; 8(9):e1629779. PubMed ID: 31428529
[TBL] [Abstract][Full Text] [Related]
62. Lymphocyte recovery rate using H6000.
Kay L; Locke D
J Clin Pathol; 1986 Feb; 39(2):234. PubMed ID: 16811162
[No Abstract] [Full Text] [Related]
63. Neutrophil to lymphocyte ratio (NTLR) predicts local control and overall survival after stereotactic body radiotherapy (SBRT) in metastatic sarcoma.
Somasundaram E; Anderson PM; Smile TD; Halima A; Broughman JB; Reddy CA; Parsai S; Scott JG; Chan T; Campbell S; Angelov L; Zahler S; Trucco M; Thomas SM; Johnson S; Qi P; Magnelli A; Murphy ES
Sci Rep; 2023 Nov; 13(1):19256. PubMed ID: 37935813
[TBL] [Abstract][Full Text] [Related]
64. Immature platelet fraction predicts early marrow recovery after severe chemotherapy associated neutropenia.
Salvador C; Meryk A; Hetzer B; Bargehr C; Kropshofer G; Meister B; Anliker M; Crazzolara R
Sci Rep; 2023 Feb; 13(1):3371. PubMed ID: 36849723
[TBL] [Abstract][Full Text] [Related]
65. Bioinformatics analysis of the key genes in osteosarcoma metastasis and immune invasion.
Liang J; Chen J; Hua S; Qin Z; Lu J; Lan C
Transl Pediatr; 2022 Oct; 11(10):1656-1670. PubMed ID: 36345453
[TBL] [Abstract][Full Text] [Related]
66. Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide.
Skubitz KM; Domingo-Musibay E; Lindgren BR; Cheng EY
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884480
[TBL] [Abstract][Full Text] [Related]
67. Natural Killer Cell Recognition and Control of Epithelial Cancers.
de Souza Fernandez Pereira M; Carr DR; Gatti-Mays ME; Olsen MR; Setty BA; Shahwan KT; Lee DA
Cancer J; 2022 Jul-Aug 01; 28(4):263-269. PubMed ID: 35880935
[TBL] [Abstract][Full Text] [Related]
68. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
Quamine AE; Olsen MR; Cho MM; Capitini CM
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199783
[TBL] [Abstract][Full Text] [Related]
69. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma.
Yapar A; Tokgöz MA; Yapar D; Atalay İB; Ulucaköy C; Güngör BŞ
Jt Dis Relat Surg; 2021; 32(2):489-496. PubMed ID: 34145828
[TBL] [Abstract][Full Text] [Related]
70. Future Directions in the Treatment of Osteosarcoma.
Smrke A; Anderson PM; Gulia A; Gennatas S; Huang PH; Jones RL
Cells; 2021 Jan; 10(1):. PubMed ID: 33467756
[TBL] [Abstract][Full Text] [Related]
71. Prospects for NK Cell Therapy of Sarcoma.
Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
[TBL] [Abstract][Full Text] [Related]
72. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
Chew HY; Chan V; Simpson F; Dolcetti R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207697
[TBL] [Abstract][Full Text] [Related]
73. Sarcoma treatment in the era of molecular medicine.
Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
[TBL] [Abstract][Full Text] [Related]
74. Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy.
Anderson PM; Lalla RV
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32512833
[TBL] [Abstract][Full Text] [Related]
75. Natural Killer Cell Immunotherapy for Osteosarcoma.
Tullius BP; Setty BA; Lee DA
Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
[TBL] [Abstract][Full Text] [Related]
76. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
Yang Q; Chen T; Yao Z; Zhang X
World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
[TBL] [Abstract][Full Text] [Related]
77. Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma.
Lee JA; Oh HL; Kim DH; Lim JS
Korean J Pediatr; 2019 Feb; 62(2):62-67. PubMed ID: 30304898
[TBL] [Abstract][Full Text] [Related]
78. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
Murad JM; Graber DJ; Sentman CL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):176-183. PubMed ID: 29909918
[TBL] [Abstract][Full Text] [Related]
79. Detection of circulating tumor DNA in patients with osteosarcoma.
Barris DM; Weiner SB; Dubin RA; Fremed M; Zhang X; Piperdi S; Zhang W; Maqbool S; Gill J; Roth M; Hoang B; Geller D; Gorlick R; Weiser DA
Oncotarget; 2018 Feb; 9(16):12695-12704. PubMed ID: 29560102
[TBL] [Abstract][Full Text] [Related]
80. Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia.
Rolf N; Smolen KK; Kariminia A; Velenosi A; Fidanza M; Strahlendorf C; Seif AE; Reid GSD
Cancer Immunol Immunother; 2018 Feb; 67(2):225-236. PubMed ID: 29052781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
